ANGEL1: A Drug Target and Biomarker for Angiotensin-Induced Hyperkalemia

Target Name: ANGEL1

NCBI ID: G23357

ANGEL1

ANGEL1: A Drug Target and Biomarker for Angiotensin-Induced Hyperkalemia

Angiotensin-induced hyperkalemia (AIH) is a serious medical condition that can be caused by an imbalance of angiotensin II, a hormone that causes blood vessels to constrict and raise blood pressure. This condition can lead to high levels of potassium in the blood, which can cause muscle weakness, cardiac arrhythmias, and other serious complications if left untreated.

The discovery of ANGEL1, a protein that is regulated by angiotensin II, has the potential to be a drug target and biomarker for AIH. ANGEL1 has been shown to play a crucial role in the regulation of blood pressure, and alterations in ANGEL1 levels have been linked to the development and progression of AIH.

research has shown that ANGEL1 levels are elevated in individuals with AIH, and that these individuals have improved response to angiotensin receptor blockers (ARBs), which are commonly used to treat this condition. Additionally, studies have shown that ANGEL1 levels are decreased in individuals who have died from AIH, suggesting that it may be a useful biomarker for this deadly condition.

The ANGEL1 protein is a member of the superfamily of transmembrane proteins, which means that it spans the entire thickness of the cell membrane. It is located in the endoplasmic reticulum, a structure that removes proteins from the end of the ER and transports them to their final destinations in the cell. ANGEL1 is also known as angiotensin-converting enzyme 1, and its function is to regulate the activity of angiotensin II.

In addition to its role in regulating angiotensin II, ANGEL1 is also involved in the regulation of several other physiological processes that are important for human health. For example, ANGEL1 has been shown to play a role in the regulation of inflammation, and it is thought to influence the production of pro-inflammatory cytokines. It is also involved in the regulation of cell survival and proliferation, and has been shown to influence the development and progression of several types of cancer.

The ANGEL1 gene was identified and characterized in the late 1990s, and it has since been shown to be involved in the regulation of angiotensin II activity. Several studies have since confirmed that ANGEL1 plays a crucial role in the regulation of blood pressure, and that alterations in ANGEL1 levels are associated with the development and progression of AIH.

One of the challenges in the treatment of AIH is the development of resistance to angiotensin receptor blockers (ARBs), which are commonly used to treat this condition. This is because ARBs can cause significant improvements in blood pressure, but can also cause a variety of side effects, such as dizziness, headache, and nausea.

Research has shown that ANGEL1 plays a role in the development of resistance to ARBs, and that individuals with higher ANGEL1 levels are more likely to develop resistance to these medications. Additionally, studies have shown that ANGEL1 levels are decreased in individuals who have died from AIH, suggesting that it may be a useful biomarker for this deadly condition.

In conclusion, ANGEL1 is a protein that is regulated by angiotensin II and has been shown to play a crucial role in the regulation of blood pressure. Its levels are elevated in individuals with AIH, and it has been shown to play a role in the development and progression of this condition. As a result, ANGEL1 has the potential to be a drug target and biomarker for AI

Protein Name: Angel Homolog 1

The "ANGEL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANGEL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets